logo
Plus   Neg
Share
Email

Perrigo Settles Patent Litigation For Generic Version Of Finacea Foam, 15%

Perrigo Co. plc (PRGO) said Tuesday that it has settled its Hatch-Waxman litigation relating to its tentatively-approved generic version of Finacea Foam (azelaic acid) 15% pursued by LEO Pharma A/S, LEO Pharma Inc., and Foamix Pharmaceuticals Ltd. The company noted that terms of the settlement are confidential.

As measured by IQVIA, annual market sales for the 12 months ending February 2019 were about $61 million.

"This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Our R&D, operations and legal teams continue to work diligently and relentlessly to advance our pipeline of specialized generic products that provide high quality alternatives, and savings to patients and payors," said Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT